Universal Biosensors Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Coleman Craig E., was filed 28 May 2024.
Universal Biosensors Inc: what insiders have been doing
Universal Biosensors Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Universal Biosensors Inc. The previous disclosure was published on 28 May 2024.
Our records for Universal Biosensors Inc go back to 2008, with 116 purchases and 12 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
- 1,421,293 shares@ US$0.112.8% of flowCommon StockSEC:0001104659-24-065367:0Canonical exit: 25 Aug 2024 (T+90)
- 275,000 shares@ US$0.119.9% of flowCommon StockSEC:0001437749-24-018514:0
- 275,000 shares@ US$0.1117.0% of flowCommon StockSEC:0001437749-24-018513:0
- 1,000,000 shares0Common StockSEC:0001437749-24-014444:1
- 217,182 shares@ US$0.150.1% of flowCommon StockSEC:0001104659-24-057126:1Canonical exit: 30 Jul 2024 (T+90)
- 23,055 shares@ US$0.151.1% of flowCommon StockSEC:0001437749-24-014447:1
- 30,000 shares@ US$0.151.5% of flowCommon StockSEC:0001437749-24-014447:2
- 1,000,000 shares0Common StockSEC:0001437749-24-014444:0
- 99,077 shares@ US$0.1530.6% of flowCommon StockSEC:0001437749-24-014446:0
- 180,116 shares@ US$0.1515.4% of flowCommon StockSEC:0001437749-24-014448:0
- 29,289,424 shares@ US$0.1580.2% of flowCommon StockSEC:0001104659-24-057126:0Canonical exit: 30 Jul 2024 (T+90)
- 10,000 shares@ US$0.150.5% of flowCommon StockSEC:0001437749-24-014447:0
- 1,000,000 shares@ US$0.203.6% of flowCommon StockSEC:0001104659-24-038941:0Canonical exit: 23 Jun 2024 (T+90)
- 1,364,666 shares@ US$0.2089.6% of flowCommon StockSEC:0001437749-24-009315:0
- 75,000 shares@ US$0.19878.5% of flowCommon StockSEC:0001437749-23-034051:0
- 100,000 shares@ US$0.220.4% of flowCommon StockSEC:0001104659-23-100218:0Canonical exit: 10 Dec 2023 (T+90)
- 95,983 shares@ US$0.1679100.0% of flowCommon StockSEC:0001437749-23-024351:0Canonical exit: 28 Sept 2023 (T+90)
- 150,000 shares@ US$0.2521.4% of flowCommon StockSEC:0001437749-23-006590:0
- 50,000 shares0Common StockSEC:0001437749-23-000191:0
- 50,000 shares0Common StockSEC:0001437749-23-000192:0
- 200,000 shares@ US$0.2326.7% of flowCommon StockSEC:0001437749-22-028946:0
- 82,152 shares@ US$0.240.1% of flowCommon StockSEC:0001104659-22-119348:1Canonical exit: 13 Feb 2023 (T+90)
- 17,848 shares@ US$0.240.0% of flowCommon StockSEC:0001104659-22-119348:2Canonical exit: 14 Feb 2023 (T+90)
- 50,000 shares@ US$0.250.2% of flowCommon StockSEC:0001104659-22-119348:0Canonical exit: 9 Feb 2023 (T+90)
- 200,000 shares@ US$0.281.1% of flowCommon StockSEC:0001104659-22-092425:0Canonical exit: 15 Nov 2022 (T+90)
25 of 243 declarations
About Universal Biosensors Inc
Universal Biosensors Inc. (UBI) is a specialty biosensor company focused on electrochemical cell technology and portable point-of-care testing. For French-speaking investors analyzing the name in a U.S. context, it is important to note that the company is a United States entity for SEC purposes, and its insider activity is reported through SEC Form 4 filings, while the shares are tracked in the U.S. market ecosystem associated with NYSE/NASDAQ-style coverage. Operationally, however, the company is headquartered and manufactures primarily from Rowville, Victoria, Australia, where it also maintains its R&D and production footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1678533/000110465924065367/xslF345X03/tm2415677-1_4seq1.xml))
Universal Biosensors was built around proprietary biosensor technology designed to convert biochemical reactions into fast, low-cost, and user-friendly test results. The company’s core ambition is to develop a broad family of biosensor test strips that can be used with handheld analyzers across multiple end markets. That technological focus is the company’s main competitive differentiator: rather than competing as a broad diagnostics conglomerate, UBI operates as a niche platform developer with expertise in strips, analyzers, and assay development. ([universalbiosensors.com](https://universalbiosensors.com/about-us/))
Read moreShow less
Its principal business lines currently span human health, animal health, wine testing, and laboratory services. In human health, the Xprecia Prime Coagulation Analyzer is the key branded platform, complemented by Hemostasis Reference Laboratory (HRL), a Canadian blood testing laboratory that supports hemostasis-related services. In non-medical applications, Sentia Wine Analyzer is aimed at winemakers and vineyards that need rapid on-site measurements such as glucose, fructose, total acid, titratable acidity, malic acid, and sulfur dioxide. In animal health, PETRACKR is positioned as a veterinary blood glucose monitoring system. UBI also indicates a broader pipeline of biosensor opportunities, including environmental and agricultural applications. ([universalbiosensors.com](https://universalbiosensors.com/products/))
From a market-positioning standpoint, UBI is a small-cap specialist operating against larger diagnostics and life-science competitors. Its competitive edge lies in portability, ease of use, and the ability to deliver quantitative results at the point of need. That said, the company’s scale is limited, and commercialization appears to depend heavily on partnerships, distribution agreements, and product-specific execution rather than a large direct-sales infrastructure. Its geographic presence is international, but the operating center of gravity remains Australia, with commercial relevance extending into North America and other regions through product deployments and laboratory activity. ([universalbiosensors.com](https://universalbiosensors.com/about-us/))
Recent disclosures suggest a challenging financial backdrop. In its 2025 half-year reporting, UBI stated that its cash and cash equivalents were only sufficient to fund operations into Q3 2025, raising substantial doubt about its ability to continue as a going concern, and management said it was pursuing revenue growth, partnerships, asset sales, debt financing, and equity issuance. For investors, this means the name combines attractive technology exposure with elevated balance-sheet and execution risk. ([universalbiosensors.com](https://universalbiosensors.com/wp-content/uploads/Q2-2025-10-Q-bannerless.pdf))
